To include your compound in the COVID-19 Resource Center, submit it here.

BioSight reports Phase I/II data for AML candidate

BioSight Ltd. (Airport City, Israel) reported final data from 14 evaluable patients with newly diagnosed acute myelogenous leukemia (AML) in the Phase

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE